Answer:
If you are looking for persuasive information for funding Alzheimer's disease research, you may want to consider the following points:
• Alzheimer's disease is a devastating and incurable brain disorder that affects more than 6 million Americans and 50 million people worldwide. It causes progressive memory loss, cognitive decline, behavioral changes, and ultimately death.
• Alzheimer's disease is also a major public health and economic challenge, as it places a huge burden on families, caregivers, health systems, and society. In 2021, Alzheimer's and other dementias will cost the United States an estimated $355 billion, and this number is projected to rise to more than $1.1 trillion by 2050.
• Alzheimer's disease research is essential to find effective ways to prevent, diagnose, treat, and cure this devastating disease. Research can also improve the quality of life and care for people living with Alzheimer's and their caregivers, and reduce the social and economic impact of the disease.
• Alzheimer's disease research is supported by various sources, such as the federal government, the pharmaceutical industry, nonprofit organizations, and private donors. However, the current level of funding is insufficient to meet the growing needs and opportunities in this field.
• The federal government is the largest funder of Alzheimer's disease research in the United States, mainly through the National Institutes of Health (NIH). Thanks to the advocacy efforts of the Alzheimer's Association and the Alzheimer's Impact Movement (AIM), Congress has increased NIH funding for Alzheimer's research from $448 million in 2011 to more than $3.7 billion in 2022. However, this amount is still far below the estimated $10 billion per year that experts recommend to achieve breakthroughs by 2025.
• The pharmaceutical industry is another major funder of Alzheimer's disease research, investing billions of dollars in developing new drugs and therapies. However, drug development is a risky and costly process, with many failures and setbacks along the way. The recent approval of aducanumab (Aduhelm) by the Food and Drug Administration (FDA) was a milestone for Alzheimer's research, but it also raised controversy and uncertainty about its efficacy, safety, and affordability. More research is needed to confirm and expand the benefits of this drug and to discover other potential treatments.
• Nonprofit organizations and private donors also play a vital role in supporting Alzheimer's disease research, especially in areas that are underfunded or neglected by other sources. For example, the Alzheimer's Association International Research Grant Program (IRGP) funds innovative and diverse projects that advance our understanding of Alzheimer's disease, identify new treatment strategies, improve care for people with dementia, and further our knowledge of brain health and disease prevention. Since 1982, the IRGP has awarded over $240 million to more than 3,000 researchers in over 50 countries.
Therefore, funding Alzheimer's disease research is a worthy and urgent cause that deserves our attention and support. By investing more resources and efforts in this field, we can hope to find solutions that will make a difference for millions of people affected by this disease and their loved ones.blush
Step-by-step explanation: